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Abstract
Purpose The present study compared the effects of mandibu-
lar advancement therapy (MAD) with continuous positive air-
way pressure therapy (CPAP) on daytime cardiac autonomic
modulation in a wide range of obstructive sleep apnea (OSA)
patients under controlled conditions in a randomized, two-
period crossover trial.
Methods Forty OSA patients underwent treatment with MAD
and with CPAP for 12 weeks each. At baseline and after each
treatment period, patients were assessed by polysomnography
as well as by a daytime cardiac autonomic function test that
measured heart rate variability (HRV), continuous blood pres-
sure (BP), and baroreceptor sensitivity (BRS) under condi-
tions of spontaneous breathing, with breathing at 6, 12, and
15/min.
Results Both CPAP and MAD therapy substantially eliminat-
ed apneas and hypopneas. CPAP had a greater effect. During
daytime with all four conditions of controlled breathing, three-
minute mean values of continuous diastolic BP were signifi-
cantly reduced for both MAD and CPAP therapy. At the same
time, selective increases due to therapy withMADwere found
for HRV high frequency (HF) values. No changes were ob-
served for BRS in either therapy mode.
Conclusions These findings indicate that both MAD and
CPAP result in similar beneficial changes in cardiac autonom-
ic function during daytime, especially in blood pressure.
CPAP is more effective than MAD in eliminating respiratory
events.
Keywords Mandibular advancement device . Obstructive
sleep apnea . Cardiac autonomic function . Blood pressure .
Continuous positive airway pressure . Heart rate variability .
Baroreceptor sensitivity
Introduction
Obstructive sleep apnea (OSA) is the most common form of
sleep-disordered breathing and affects about 5–7 % of the
adult population [1]. Repetitive collapses of the upper airways
during sleep lead to hypoxic phases with associated sleep
fragmentation and sympathetic activation, the latter of which
also persists during daytime with the resultant consequences
[2]. OSA has accordingly been confirmed as an independent
cardiovascular risk factor that may increase mortality if left
untreated [3]. Continuous positive airway pressure (CPAP)
therapy is manifestly an effective therapeutic approach. Many
studies have demonstrated that CPAP therapy reduces cardio-
vascular risk and overall mortality rate if regularly employed
by OSA patients [2–4]. CPAP therapy is accordingly recom-
mended as the standard therapy in moderate to severe OSA.
The CPAP effect can partly be explained by its reduction of
sympathetic tone not only during the night but also during
daytime [5].
In addition to investigation of blood pressure [4] and heart
rate variability (HRV) [6], measurements of baroreceptor
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sensitivity (BRS) and of systolic blood pressure variability
(SBPV) represent non-invasive methods of assessing auto-
nomic activity [7]. Regular CPAP therapy improves these pa-
rameters during the night and daytime as evidence of reduc-
tion of sympathetic hyperactivation in OSA patients [5, 8].
Many trials have dealt with the effect of CPAP on HRV [9],
and others have likewise reported the positive effect of CPAP
on BRS [9, 10].
Unfortunately, many patients demonstrate limited adher-
ence to CPAP therapy, and some patients decline this form
of treatment. There is accordingly a need for alternative ther-
apeutic approaches that are as effective as CPAP therapy—not
only with respect to symptoms but also to the cardiovascular
consequences of OSA.
Intraoral mandibular advancement devices (MAD) pro-
trude the mandible during sleep to maintain upper airway
patency [11]. A number of trials have shown comparable ef-
fects of MAD and CPAP in OSA patients with regard to
symptoms such as daytime sleepiness and driving perfor-
mance—but have also covered side effects, withdrawal rates,
and usage time [12, 13]. Although MAD evidently does not
reduce apnea-hypopnea index (AHI) by the same amount as
CPAP [12–14], more favorable side effects, withdrawal rates,
and usage time may be explained by better compliance and
quality of life in patients who employ MAD compared with
those who use CPAP [13]. This was also confirmed by other
randomized controlled trials that investigated the effects of
both therapies [15–21]. MAD has thus been proposed as al-
ternative therapeutic approach for mild to moderate OSA, in
accordance with existing guidelines [2, 22]. Some investiga-
tors have demonstrated subjective benefits of MAD for pa-
tients classified with severe OSA [13, 18, 23]. Studies of
MAD therapy, however, are often not comparable. Further-
more, the few studies that until now have examined the effects
of MAD therapy on cardiovascular parameters have arrived at
contradictory findings. Gotsopoulus et al. [24] found a small
reduction in diastolic blood pressure during daytime, whereas
Andren et al. [25] reported improvement in systolic blood
pressure. Phillips et al. [13] showed that regular use of neither
CPAP nor MAD for 1 month can improve 24-h ambulatory
mean blood pressure, whereas they are comparably effective
with respect to daytime sleepiness and quality of life.
Little is known about the effect of MAD therapy on
autonomic activity parameters. One study investigating
daytime HRV parameters [26] found that 3 months of
MAD therapy improved cardiac autonomic modulation.
Dal-Fabbro et al. [27] investigated effects of 1-month
MAD and CPAP therapy on HRV during sleep and
found a number of beneficial changes for both
therapies.
To date, none of the previous studies has specifically ex-
plored in parallel the effect of MAD on daytime blood pres-
sure, HRV, BRS, and SBPV. There are likewise no systematic
comparisons betweenMAD and CPAP for these parameters in
the same patients.
The present study therefore aimed to evaluate the effect of
MAD and CPAPwith regard to cardiovascular parameters and
autonomic activity in a two-period crossover design in which
the patients were either randomized to the sequence MAD–
CPAP (12 weeks of MAD followed by 12 weeks of CPAP) or
the sequence CPAP–MAD (3 months of CPAP followed by
3 months of MAD).
Subjects and methods
Participants
Eighty-four patients with suspicion of OSA syndrome were
asked to participate in the study. The study was approved by
the local ethics committee of the university hospital Charité—
Universitätsmedizin Berlin, and participants gave their written
consent for participation.
Inclusion criteria were an AHI of ≥5/h and an age of
≥18 years. Patients with severe OSA (AHI >30/h) requiring
treatment were included only if they did not demonstrate clear
indication for CPAP such as a severe cardiovascular risk, e.g.,
myocardial infarction, stroke, atrial fibrillation, resistant hy-
pertension, or heart failure. An essential element for inclusion
of any patient was a clinical symptom complex, as well as
suffering owing to lack of refreshing sleep.
Exclusion criteria were drug abuses, any medication intake
that could influence sleep, any presence of sleep disorders
other than OSA, any kind of specific medication for OSA in
the patient’s case history, prior use of any form of PAP thera-
py, any prior pharyngeal surgery (UPPP, LAUP, or RFT) for
OSA therapy, any psychiatric or neurological diseases previ-
ously known or arising during the study that could impair
compliance, atrial fibrillation, any medication that could affect
heart rate, craniomandibular disorders with restricted mobility
of the lower jaw (especially restrictions to protrusion), acute to
subacute dental treatment requirements (e.g., caries treat-
ment), >8 stable natural teeth per jaw (with maximum average
Periotest value per tooth <20), acute periodontal disease, class
III dental relationship with anterior crossbite, participants in
orthodontic retention for less than 6 months, and discontinu-
ation of therapy or interruption of therapy for more than
1 week.
Participants who had taken part in a clinical pharmacolog-
ical trial up to 4 weeks before entering the study were also
excluded.
Study procedure
Patients with reported symptoms of OSA were asked to par-
ticipate in the study. After receiving written consent for
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participation in the study, they received a 6-channel ambula-
tory sleep apnea monitoring device (Embletta pds, Embla Inc.,
Broomfield, CO, USA), which included recording airflow,
snoring, thoracic and abdominal efforts, oxygen saturation,
leg movements, and body position. In addition to a physical
examination, a general medical case history, and a specific
sleep disorder case history, patients were asked to complete
the form on the Epworth Sleepiness Scale (ESS) as well as the
Insomnia Severity Index (ISI). A dental examination and
screening for craniomandibular disorders (CMD) were per-
formed by a dentist.
If patients were eligible by the applied inclusion/exclusion
criteria, theywere randomized in a crossover fashion to either a)
receivingMAD (SomnoDent®, Somnomed EuropeAG, Zurich,
Switzerland) as initial therapy for 12 weeks followed by CPAP
(REMstar Pro, Philips Respironics, Murrysville, PA, USA)
therapy for another 12 weeks (sequence group MAD–CPAP)
or b) receiving CPAP as initial therapy for 12 weeks followed
by a MAD therapy for another 12 weeks (sequence group
CPAP–MAD). The entire study protocol is illustrated in Fig. 1.
If patients had been randomized to initially receive MAD
therapy, the MAD was individually produced and fitted to the
patient 1–2 weeks prior to the beginning of the therapy (T1)
by the manufacturer (Somnomed Europe AG, Zurich, Swit-
zerland) and by a dentist. At T1 in both treatment arms, pa-
tients were investigated by polysomnography (PSG) for three
consecutive nights without gap. The first night served as base-
line PSG, and the subsequent two nights were titration nights
to the initial therapy upon randomization. Criteria for the re-
maining in the study were an AHI of at least 5/h and exclusion
of a relevant PLMD syndrome (PLMI <10/h) or other relevant
movement disorders during baseline PSG.
After baseline PSG on the following day, patients were
investigated by a cardiac autonomic function test.
For patients who had been randomized to receive the MAD,
titration with the MAD took place during the first of the two
titration nights with an individually adjusted protrusion of up to
70 % of the possible maximum. If the AHI remained ≥10/h after
the first titration night, the protrusion was individually increased,
as recorded by a gauge by another 10 % of the patient’s maxi-
mum protrusion capacity during the second titration night.
For patients who had been randomized to receive CPAP
therapy during the two titration nights, manual titration was
performed to eliminate apneas, hypopneas, oxygen
desaturations, and respiratory arousals.
After the three baseline PSG nights at T1, the patients were
sent home for 12 weeks of continuous use of therapy during
sleep with either MAD or CPAP. Afterward, the patients were
invited to the sleep lab for another 3 consecutive nights with-
out gap by PSG (T2).
For patients who had been randomized to receive the MAD
as the following therapy, the MADwas individually produced
and fitted to the patient by a dentist 1–2 weeks prior to the
beginning of this therapy (T2).
During the first PSG at T2, patients were investigated while
using the therapy that they had initially applied to measure the
12-week therapeutic effect on sleep.
After PSG on the following day, patients were again inves-
tigated by a cardiac autonomic function test to measure the 12-
week therapeutic effect of the initial therapy on daytime car-
diovascular functions.
The subsequent two PSGs of T2 served as titration nights
for the following therapy mode and were performed as de-
scribed for T1. After the three subsequent PSG nights at T2,
patients were sent home for 12 weeks of continuous use of the
following therapy. After this period, patients were invited to
the sleep lab for a single night with PSG (T3). Patients were
































































- personal reasons (n=2)
- technical failure (n=1)
Dropouts:
- insufficient compliance (n=2)




Fig. 1 Flow diagram of the study: T1 at the beginning of therapy, T2 after 12 weeks of initial therapy, and T3 after another 12 weeks with the following
therapy
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by the therapy that they had employed during the previous
12 weeks. After PSG on the following day, patients were
investigated once again by a cardiac autonomic function test
to measure the 12-week therapeutic effect on daytime cardio-
vascular functions.
Polysomnography
PSG was performed in a sleep lab certified by the German
Sleep Society Board according to the American Academy of
Sleep Medicine (AASM) guidelines by using an Embla
N7000 recorder (Embla systems, Broomfield, CO, USA).
Manual scoring of sleep resulted in the following parame-
ters: percentage of sleep stages N1, N2, N3, and R of total
sleep time (% TST); sleep latency (SL); wake time after sleep
onset (WASO); and sleep efficiency (SE). Manual scoring of
respiratory events during sleep enabled calculation of the ap-
nea index (AI), the hypopnea index (HI), the AHI, and the
oxygen desaturation index (ODI).
Scoring of sleep and respiratory events took place accord-
ing to the AASM guidelines.
Cardiac autonomic function test
The cardiac autonomic function test was performed in the
morning hours during wakefulness in a quiet room of the sleep
lab. Patients were instructed not to use caffeine or vasoactive
drugs during the morning of the test. Patients were studied in a
45° head-up position and were trained in metronomically con-
trolled breathing at varying respiration frequencies, for a du-
ration of 5 min in each case. Non-invasive continuous blood
pressure was recorded with the Portapres® system (Finapres
Medical Systems, Amsterdam, The Netherlands). This meth-
od correlates well with intra-arterial blood pressure values and
proved to be valid for time- and frequency-domain analysis of
blood pressure variability and BRS [28]. In parallel, ECG
(lead II), respiration with a thoracic effort belt, and nasal air-
flow were recorded using a PSG recorder (Embla systems,
Broomfield, CO, USA). Subjects were instructed to breathe
a) spontaneously, b) at a fixed rate of 6/min, c) at a fixed rate of
12/min, and d) with a fixed rate of 15/min. This protocol had
likewise been used in earlier studies [29–31]. The fixed
breathing rates were presented to the patients by a metronome.
The sequence of these episodes of forced breathing, uniformly
specified for every patient, included breaks of 2 min in which
Riva-Rocci office blood pressure measurements were taken
before raising the breathing rate.
The sampling rate was set to 200 Hz for the ECG and the
continuous finger blood pressure signals and to 50 Hz for the
respiration signals. The recording time duration for the four
subsequent breathing modalities was 5 min each.
Continuous heart rate and blood pressure analysis
The ECG and the continuous blood pressure signals recorded
with the cardiac autonomic function test were analyzed using
the MATLAB® software (The Math-Works Inc., Natick, MA,
USA), with algorithms as previously described [29, 32]. After
offline filtering of 5-min signals using a Butterworth band
pass (0.3–70 Hz) for each subsequent heartbeat, measurement
of the following took place by peak-detection algorithms: the
RR interval, the systolic blood pressure, and the diastolic
blood pressure. Beat-to-beat mean blood pressure values were
obtained by integration of continuous blood pressure values
between subsequent heartbeats. Artifacts were thereafter re-
moved and episodes of 3 min in which the breathing pattern
was stable were selected for further analysis from the 5 min
records. Interpolation of the time series then followed at 4 Hz
by using a cubic spline interpolation algorithm.
In the time domain, we calculated the mean heart rate, the
standard deviation of NN intervals (SDNN), and the root
mean square of successive differences (RMSSD). In the fre-
quency domain, fast Fourier transformation was applied to
calculate power spectra of HRV and SBPV. For each of the
two spectra, the low frequency (LF 0.04 to 0.15 Hz) and high
frequency (HF 0.15 to 0.4 Hz) spectral bands were calculated.
For subjects in the supine position under controlled respi-
ration without pharmacological or physical interventions, it
can be assumed that the HRV HF band is primarily modulated
by vagal activity, whereas the LF band reflects both sympa-
thetic and vagal autonomic activity [33]. The LF/HF-HRV
ratio was calculated as a surrogate for sympathovagal balance.
An increase in the LF/HF-HRV ratio indicates a shift toward a
sympathetic predominance in which higher sympathetic activ-
ity is causative as long as the HF component remains un-
changed. SBPV components in the LF range are related to
sympathetic activity, although this relationship is not specific.
HF-SBPV component modulations are due to mechanical ef-
fects of respiration.
BRS is based on the permanent activity of the baroreflex
feedback loop, in which amplitude fluctuations of blood pres-
sure are transferred to corresponding heart rate changes. By
use of spectral analysis of spontaneous heart and systolic
blood pressure changes, it was possible to calculate spontane-
ous BRS by applying the square root of the ratio of RR inter-
val and systolic blood pressure (SBP) power spectra. BRS
values are expressed inmilliseconds per millimeter ofmercury
(msec/mmHg).
This calculation was performed individually for the LF
(0.04 to 0.15 Hz) and HF (0.15 to 0.4 Hz) spectral bands,
which produced α-LF and α-HF [34] results. The squared
coherence function (k2) was used to evaluate the statistical
reliability of α-LF and α-HF. Data were further utilized if k2
exceeded 0.56 [35]. Under normal breathing conditions, α-LF
shows the gain in the ratio of arterial pressure to RR interval in
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the spectral region not linked to breathing frequency. The α-
HF component reflects the gain in the spectral region of the
breathing frequency [34]. As a final point, α-tot was calculat-
ed as the mean of α-LF and α-HF and serves for evaluation of
the overall baroreceptor gain [34].
Statistics
For all statistical analysis, we set the alpha level at p<0.05 and
employed the IBM software SPSS® Statistics, version 20.0
(IBM Corp., Armonk, NY, USA). Values are presented as
mean±standard deviation (SD). Data presented in figures in-
dicate values for the 5th, 25th, 50th (median), 75th, and 95th
percentiles.
To test for possible carryover effects of the therapy modes,
the Mann–Whitney test was employed between sum values of
sequence groups MAD–CPAP and CPAP–MAD.
To test for differences between measured values for base-
line, 12 weeks of MAD therapy, and 12 weeks of CPAP ther-
apy for parameters involving sleep, respiration, and the cardi-
ac autonomic function test, the Friedman test was employed.
Post-hoc analysis to identify significant pairs was performed
by applying the Wilcoxon test.
To test for differences between MAD and CPAP treatment
modalities, the Mann–Whitney test was used for difference




Out of n=84 patients with suspicion of OSAwho were initially
invited to participate, n=48 were included in the study on the
basis of inclusion and exclusion criteria. Reasons for exclusion
were periodontitis (n=20), phobia of dental work (n=3), an
AHI of <5/h (n=5), the occurrence of a central sleep apnea
syndrome (n=1), and personal reasons (n=7). After a period
of 2×12weeks, n=40 patients (m=33, w=7) successfully com-
pleted the study. Causes for discontinuation of the study were
insufficient compliance with CPAP therapy (n=2), personal
reasons (n=2), intolerance of CPAP therapy (n=3), and data
loss due to technical failure (n=1). Mean age was 49.5±
11.8 years and BMI was 28.3±4.7 kg/m2. Mild sleep apnea
(AHI 5 to 15/h) was determined in n=3 patients, moderate sleep
apnea (AHI >15 to 30/h) in n=24, and severe sleep apnea (AHI
>30/h) in n=13. Mean ESS score was 9.2±3.9, and a value of
ESS ≥10—indicating an increased tendency to fall asleep—was
established among half the patients. The average ISI score was
10.8±4.9. Complaints of mild insomnia, expressed by an ISI
score of 8 to 14, was seen in n=22 patients, and moderate
insomnia, with an ISI score 15 to 21, was observed in another
n=7 patients.
Therapeutic effects of MAD and CPAP on PSG measures
No significant carryover effects on sleep structure or respira-
tion were disclosed by PSG for sequence groupsMAD–CPAP
and CPAP–MAD.
Sleep structure
After 12 weeks of therapy, NREM sleep stage N1 was reduced
by 7.7%-TST forMAD (p<0.01) and by 11.6%-TST for CPAP
(p<0.01). Comparison of treatment modalities disclosed that the
reduction was more pronounced after CPAP use than after MAD
(p<0.001). Rapid eye movement (REM) sleep increased by
2.3 %-TST for MAD (p<0.01) and by 3.9 %-TST for CPAP
(p<0.01) in reference to baseline PSG values. Slow wave sleep
(SWS) stageN3 likewise increased by 3.9%-TST (p<0.01) after
12 weeks of CPAP therapy, whereas for MAD, no significant
changes were found. Comparison of CPAP and MAD results
revealed no differences between treatment modalities with re-
spect to sleep stages REM and N3. Parameters N2, WASO,
SL, and SE remained unchanged with therapy in both treatment
modalities. Also, comparison of CPAP and MAD results re-
vealed no differences between treatment modalities for these
parameters (Table 1).
Respiratory parameters
Twelve weeks of treatment with MAD and with CPAP led
with both modalities to changes in respiratory parameters.
Mean oxygen saturation values of 94.7±1.5 % (range of
90.0 to 97.9 %) at baseline did not change after 12 weeks of
Table 1 Effect of CPAP and MAD therapy on parameters of sleep
structure from polysomnography (PSG)
Parameter Baseline, n=40 MAD, n=40 CPAP, n=40
N1 [% TST] 21.0±13.0 13.3±7.5* 9.4±4.2*,**
N2 [% TST] 44.7±10.2 47.2±11.4 46.7±13.8
N3 [% TST] 18.9±10.0 21.3±11.0 22.8±11.7*
REM [% TST] 15.9±5.6 18.2±5.2* 19.9±5.0*
WASO [min] 51.0±34.9 44.2±39.2 58.5±46.9
TST [min] 400.3±51.4 394.5±59.4 400.5±59.1
SE [%] 86.9±7.9 88.2±9.4 85.8±11.6
SL [min] 15.9±12.4 19.4±19.7 20.2±19.8
Values are means±SD
CPAP continuous positive airway pressure therapy, MAD mandibular
advancement therapy, REM rapid eye movement,WASOwake after sleep
onset time, SE sleep efficiency, SL sleep latency
*p<0.01 for comparison MAD vs. baseline or CPAP vs. baseline;
**p<0.001 for comparison CPAP vs. MAD
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MAD therapy (94.8±1.2 %, range of 90.0 to 97.9%), but after
CPAP therapy (95.9±1.1 %, range of 93.8 to 98.0 %) a reduc-
tion of 1.2 % (p<0.001) became apparent. Comparison of
CPAP with MAD disclosed significant difference between
treatment modalities (p<0.001). The ODI changed from
21.5±14.8/h (range of 0.6 to 67.1/h) at baseline to 11.8±
11.4/h (range of 0.7 to 59.4/h) for MAD therapy (p<0.001)
and to 4.0±6.5/h (range of 0.0 to 29.7/h) for CPAP therapy
(p<0.001). Comparison of CPAP to MAD revealed a signifi-
cant difference between treatment modalities (p<0.001).
The mean baseline AHI of 28.5±16.5/h (range of 10.8 to
83.6/h) diminished with MAD treatment by 14.8/h (p<0.001)
to 13.7±12.0/h (range of 1.3 … 59.6/h), whereas with CPAP
treatment, a reduction by 25.0/h (p<0.001) to 3.5±5.2/h
(range 0.0 … 23.6/h) became evident (Fig. 2). Separate anal-
ysis of apneas and hypopneas revealed for the AI a reduction
from 17.8±16.5/h (range of 0.3… 23.6/h) at baseline to 6.8±
10.3/h (range of 0.0 … 55.1/h) for MAD therapy (p<0.001)
and to 1.1±1.7/h (range of 0.0 … 8.2/h) for CPAP therapy
(p<0.001), whereas for the HI, a reduction from 11.1±7.0/h
(range of 0.0… 37.6/h) at baseline to 7.0±6.7/h (range of 0.7
… 34.4/h) forMAD therapy (p<0.01) and to 2.4±3.8/h (range
of 0.0 … 16.2/h) for CPAP therapy (p<0.001) was present.
When comparing CPAP to MAD, there was a significant dif-
ference between treatment modalities for the AHI (p<0.001),
the AI (p<0.001), and for the HI (p<0.001). For treatment
with MAD in n=8 patients (20.0 %) and for CPAP in 33
patients (82.5 %), reduction in the number of breathing cessa-
tions to an AHI ≤5/h was observed. With assumption of a
cutoff value of AHI ≤10/h for AHI reduction, for MAD ther-
apy, a response thereto was established in n=22 patients
(55.0 %) and for CPAP therapy, in n=37 patients (92.5 %).
Therapeutic effects of MAD and CPAP on daytime
cardiac autonomic function
Analysis of results from the cardiac autonomic modulation
test performed during daytime with the various forced breath-
ing patterns—i.e., a) spontaneously, b) with a fixed rate of
6/min, c) with a fixed rate of 12/min, and d) with a fixed rate
of 15/min—revealed no significant carryover effects between
sequence groups MAD–CPAP and CPAP–MAD.
Office blood pressure
Office systolic as well as diastolic blood pressure values mea-
sured by the Riva-Rocci method according to ESC/ESH
guidelines before each of the four forced breathing sequences
showed no differences after 12 weeks of MAD and CPAP
therapy. Comparison of CPAP and MAD results revealed no
differences between treatment modalities with respect to of-
fice blood pressure (Table 2).
Time domain values: RR interval, SDNN, RMSSD, and blood
pressure
In comparison with baseline, RR interval values as well as




*p<0.0001 for comparison MAD vs. Baseline or CPAP vs. Baseline













Fig. 2 Effect of MAD and CPAP
therapy on the apnea-hypopnea
index (AHI) as determined by
polysomnography (PSG)
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therapy. Again, comparison of CPAP with MAD results
disclosed no differences between treatment modalities. These
results were consistently found for all four applied respiratory
protocols. For RMSSD, a trend (p<0.1) for higher values after
12 weeks of therapy with MAD were found for forced breath-
ing rates of 12 and for 15/min. Comparison of CPAP andMAD
results revealed no differences between treatment modalities.
With regard to mean systolic blood pressure, neither MAD
nor CPAP values differed from baseline values, and CPAP and
MAD comparisons showed no differences between treatment
modalities.
With MAD therapy, the mean blood pressure showed a
trend for lower values in all four applied forced breathing
patterns. With CPAP therapy, a significant fall became evident
in mean blood pressure under the condition of 6/min and of a
trend toward lower values under conditions of spontaneous
breathing and of 15/min. Comparison of CPAP and MAD
results disclosed no differences between treatment modalities
(Table 2).
With MAD therapy, diastolic blood pressure was sig-
nificantly reduced by an average of 8.9 mmHg for spon-
taneous breathing (p<0.05). Values were likewise re-
duced by an average of 7.3 mmHg for 6/min (p<0.05),
and a trend for lower values became evident for 12/min
as well as for 15/min. With CPAP therapy, diastolic
blood pressure was significantly reduced by an average
of 8.4 mmHg for spontaneous breathing (p<0.05) as well
as on average by 9.5 mmHg for 6/min (p<0.05). A trend
for lower values was apparent for 15/min. Comparison of
CPAP with MAD showed no differences between treat-
ment modalities (Table 2, Fig. 3).
Frequency domain values: HRV, SBPV, and BRS
In comparison to baseline, mean HRV-LF values as well
as mean HRV-LF/HF values did not differ with either
MAD or CPAP therapy. These results consistently ap-







*p<0.05 for comparison MAD vs. Baseline or CPAP vs. Baseline
**p<0.01 for comparison MAD vs. Baseline or CPAP vs. Baseline
Baseline MAD CPAP Baseline MAD CPAP 





































































Fig. 3 Effect of MAD and CPAP therapy on three-minute mean values of continuous diastolic blood pressure recordings (BP-diast) under conditions of
spontaneous breathing, breathing at 6/min, 12/min, and 15/min, from the daytime cardiac autonomic function test
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12 weeks of MAD therapy, the HRV-HF component in-
creased by 9.59 ms2 for 12/min (p<0.05) and showed a
trend toward higher values for 15/min. Only at forced
breathing at 6/min after use of CPAP did SBPV-LF
values increase by 0.324 mmHg2 (p<0.05); SBPV-LF/
HF values demonstrated a trend toward higher values.
In comparison to baseline mean values of SBPV-HF,
α-LF, α-HF, and α-tot differed neither with MAD
therapy nor with CPAP therapy. These results were
consistently found for all four applied breathing
patterns.
Comparison of CPAP with MAD revealed that there
were no differences between treatment modalities for all
parameters of HRV, SBPV, and BRS (Table 2).
Discussion
For the first time, the effects of 12-week CPAP and 12-
week MAD therapy on cardiovascular and autonomic
parameters during daytime were investigated, under con-
ditions of controlled breathing. Both CPAP and MAD
therapy led to changes in blood pressure in patients
with mild to severe OSA. In addition, changes in
HRV values were observed for therapy with MAD. Both
CPAP and MAD therapy substantially eliminated breath-
ing cessations, with an advantage for CPAP treatment.
These findings became evident regardless of the defini-
tion of efficacy and the severity of OSA and are in line
with previous studies dealing with this topic [12–14].
Additionally, CPAP improves REM and SWS sleep,
while MAD shows a significant effect on REM sleep
only. No effects of therapy were detected for total sleep
time, wake time after sleep onset, or sleep efficiency.
With regard to parameters for vagal autonomic activ-
ity, the HRV-HF component increased with 3 months of
MAD use, but not with CPAP. Similarly, a trend toward
greater HRV RMSSD values became apparent with
MAD use. Analysis of continuous blood pressure mea-
surements from the cardiovascular autonomic function
test revealed changes in mean and diastolic pressures,
but not in systolic blood pressure. Diastolic blood pres-
sure declined markedly with both CPAP and MAD
treatment. Mean blood pressure benefited from CPAP
treatment only.
No effects were detected on daytime blood pressure
as measured with the Riva-Rocci method.
Analysis of autonomic activity in the frequency do-
main showed no effects with either treatment modality.
Merely a minor effect on HRV-HF after MAD and on
SBPV-LF after CPAP was detected after various breath-
ing frequencies. No effects on BRS were found.
We evidenced that both treatment options may im-
prove daytime blood pressure, especially diastolic. Our
primary finding was accordingly that MAD is as effec-
tive as CPAP in improving parameters of daytime car-
diac autonomic modulation, especially blood pressure.
This finding is surprising since the reduction of AHI
by MAD is less than with CPAP. With respect to effi-
ciency, the results of our study are in agreement with
previous studies [15–20, 23]. We did not establish an
exclusion criterion related to the AHI. We studied pa-
tients with a mean AHI of 28.6±16.5/h (min 10.8/h,
max 83.6/h), which is comparable to the other studies
cited. Engleman et al. [23] also included severe apneics
without restriction, whereas Aarab et al. [15], Ferguson
et al. [17], Gagnadoux et al. [18], and Lam et al. [21]
limited the AHI threshold to 40 to 60 events per hour
of sleep.
We recruited only n=13 patients with severe sleep
apnea, which may be related to the fact that we are a
specialized university center with more co-morbid pa-
tients than in an outpatient sleep center. Although we
did not treat many severe patients, it is important to note
that the higher the AHI, the higher the effect of MAD on
the AHI is. In mild sleep apnea patients, we found a
decline of AHI by about only 40 %; in moderate pa-
tients, by 43 %; and in severe patients, by 60 %. It is
therefore evidently the case that, despite primary recom-
mendation of MAD for mild to moderate OSA [2, 22], it
may also offer benefits for a subgroup of patients with
severe OSA. Some additional predictors may be supine-
predominant OSA, younger age, female gender, less obe-
sity, and certain craniofacial features [36].
The effect on sleep is comparable in both treatment
options and is limited to an improvement in REM sleep
for MAD and CPAP, and in SWS sleep for CPAP only,
which highlights another advantage of CPAP therapy. Al-
though such benefits are not dramatic, this aspect should
be kept in mind when selecting patients for a special kind
of treatment. On the other hand, it is necessary to note
that the amount of SWS before treatment was within nor-
mal ranges—which limits a possible SWS rebound. REM
sleep was reduced during the baseline night, which justi-
fied expectation of a treatment effect.
With regard to cardiac autonomic modulation, some
effect has been shown until now only for CPAP [5, 8].
HRV is apparently a prominent marker for measuring
the effect of CPAP on the autonomic system [5, 8],
but some authors also reported a positive effect of
CPAP on BRS [9, 10]. These studies, however, are
not comparable owing to methodological differences in-
volving time points at which measures were taken,
methods of detection, analysis methods, and duration
of treatment.
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We determined such effects in the present study as well. We
could not detect blood pressure changes at daytime as objec-
tified with the standard Riva-Rocci measurement, but we de-
tected blood pressure changes with the Portapres method.
These changes were considerable. A blood pressure change
of about 7 to 9 mmHg is clinically significant in comparison to
the changes reported for CPAP treatment, which are much
lower [4]. In addition, these results are in line with data from
Phillips et al. [13] who also reported a change in diastolic
blood pressure after MAD treatment, and from Gotsopoulos
et al. [24] who reported a decrease in the 24 ambulatory blood
pressure monitoring (ABPM) mean after 4 weeks of MAD
treatment in comparison to shamMAD. Barnes et al. [16] also
found a decline after 3 months of treatment in diastolic ABPM
blood pressure, but only at nighttime in comparison to CPAP
and to placebo. In general, for CPAP treatment, changes in
systolic as well as in diastolic blood pressure were reported for
daytime as well as for nighttime, but with low effect magni-
tudes [4]. The effect is more pronounced in patients with
higher blood pressure and in patients with resistant hyperten-
sion [4]. In our study, we did not include patients with resistant
hypertension. We included three patients who were being
treated with antihypertensive medication.
The effects determined in our study would have possibly
been even more pronounced if we had included patients with
elevated blood pressure or resistant hypertension. A mean RR
of 122.8/79.7 mmHg at baseline indicated that the patients
were within normal blood pressure ranges or slightly higher.
It is also worthy of note, however, that the ambulatory
ABPM is not comparable to our short-time series measure-
ment. Second, the influence of breathing on ABPM and on
our time series protocol can be different. We consequently
conducted a special breathing protocol with fixed breathing
frequencies. This allows a standardized comparison between
CPAP and MAD, but not with data evaluated without control
of respiration.
RMSSD improvement with the 3-month MAD treatment
also represents the positive effect of treatment on autonomic
tone. Nevertheless, it remains unclear why there are no signif-
icant changes after CPAP and why we could detect the chang-
es with only two breathing frequencies (12/min and 15/min).
Surprisingly, BRS did not change at daytime after 3 months
of both CPAP and MAD therapy. In addition, only small
changes were seen in HRV-HF (with MAD) and in SBPV-
LF (with CPAP). Although the changes in HRV and SBPV
indicate positive treatment effects, it should be considered that
our patients were without elevated cardiovascular risk, and no
marked elevations of HRV, BPV, or BRS were present upon
selection inclusion. These circumstances do not favor either
therapy; they rather indicate that changes in these parameters
during daytime and an improvement in these parameters with
therapy were evident presumably only in patients with severe
sleep apnea or in patients with severe co-morbidities.
Distinguishing between OSA severity groups and/or occur-
rence of cardiovascular morbidities was outside the scope of
this trial. In total, only n=13 patients (33 %) suffered from
severe sleep apnea and were free of co-morbidities. This num-
ber is low to obtain statistical meaningful results. This should
be the subject for future investigation. Furthermore, it could be
assumed that there may be acute changes during the night due
to therapy.
MAD technique issues
The results of our study are specific for the device we used. It
must be noted that different MAD devices are not comparable
with respect to efficacy and in accordance with AHI and type
of protrusion [37]. We used a custom-made individual
bimaxillary appliance, the same that Phillips et al. [13] used.
In contrast to CPAP treatment—for which we assume that
device characteristics are similar when the same pressure is
applied—there are evidently relevantMAD device differences
[37].
In addition, a sufficient number of healthy teeth for anchor-
age are an important issue in selecting patients for treatment
with MAD. Whether patients with sufficient teeth differ from
other sleep apnea patients has not yet been clarified. When
recruiting patients for the study, many could not be included
owing to dental decay, morbid teeth, or an insufficient number
of teeth. Occasionally, this makes fitting a patient with aMAD
treatment more difficult and time consuming than the CPAP
treatment. Well-organized co-operation with educated and ex-
perienced dentists is necessary to realize a patient flow with-
out many dropouts.
Study limitations
One limitation of this trial is that objective wear-time sensors
were not available; such devices were unfortunately not avail-
able for the MADs used for this trial. For CPAP it is reported
that compliance rates may influence changes in cardiac auto-
nomic modulation [8] due to therapy; therefore, there is a need
to fit MADs with wear-time sensors. Recent developments in
oral appliances allow for such measures, for example, by en-
abling installation of an embedded micro sensor thermometer
[38]. To promote good and comparable compliance rates in
both treatment arms in the present trial, study participants
were seriously advised to use the therapy for at least 6 h per
night and for at least 6 days per week. Inadequate compliance
with the instructions resulted in n=3 dropouts during the
course of the study.
Another limitation of this crossover study is that the change
of treatment modality from MAD to CPAP or CPAP to MAD
was not accompanied by a washout period, i.e., no therapy for
a number of days. A recently published review by Vroegop
et al. [39] concluded that there is some evidence that CPAP
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washout exists for some days in patients, although the inten-
sity and duration remain unclear. Therefore, some influence of
the preceding CPAP therapy on the subsequent titration to
MAD could not be excluded. Comparison of therapy se-
quences MAD–CPAP with CPAP–MAD by statistical analy-
sis, however, revealed no significant difference in results. Af-
ter 12 weeks of therapy, this effect could consequently be
neglected. For design of future crossover studies on therapeu-
tic interventions for OSA, a washout period should be
considered.
In conclusion, 12 weeks with MAD and with CPAP lead to
changes in cardiac autonomic modulation, in particular, by
lowering diastolic blood pressure. At the same time, both ther-
apy modalities resulted in significant reductions in the number
of breathing cessations, with greater significance in CPAP.
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